Phase 3 Osteoarthritis Trial, Recruiting NCT05517434 Sponsor: University Health Network, Toronto Condition: Osteoarthritis
Back to Osteoarthritis

Phase 3 Osteoarthritis Trial, Recruiting

NCT05517434
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are at least 30 years old
  • You are willing and able to follow the study schedule, attend visits, and understand instructions (spoken and written)
  • You are willing to sign a consent form to take part in the study
  • Your knee pain scores at least 4 out of 10 on a standard pain scale
  • You have ongoing, long-term pain in at least one knee; if both knees are affected, the more painful one will be treated
  • Your knee X-ray shows a moderate level of knee arthritis (classified as Grade 2 or 3 on a standard scale called the Kellgren-Lawrence scale)
  • Your Body Mass Index (BMI) — a measure of body weight relative to height — is 30 or below

Who may not be able to join:

  • You have had an injection into the knee (such as steroid, hyaluronic acid, PRP, or a similar treatment) in the past 6 months

  • Your knee has a significant alignment problem, such as being noticeably bow-legged or knock-kneed (confirm with trial site)

  • You have another knee problem causing pain or swelling, such as a torn ligament, torn meniscus, or cartilage damage

  • You have an active infection in the knee being studied

  • You have been diagnosed with certain types of arthritis or joint conditions, including rheumatoid arthritis, gout, psoriatic arthritis, or several other related conditions (confirm with trial site for the full list)

  • You have been diagnosed with leukemia, another blood cancer, cancer that has spread to other parts of the body, or you are currently receiving or planning chemotherapy

  • You have poor blood or fluid circulation in the leg being studied

  • You have a known allergy to local anaesthetic medications

  • You have a medical condition that affects blood clotting, such as haemophilia

  • You have had knee surgery (arthroscopy) in the past 6 months

  • You have used opioid painkillers daily for the past 3 months, taken anti-inflammatory medications (like ibuprofen) within 1 week of the procedure, or are unable to stop blood-thinning medications

  • You have used steroid tablets or similar medications for a long-term condition within the past 3 months

  • You have a condition or treatment that weakens your immune system, or you currently have an active infection

  • For one part of the study (Study 1): If not enough bone marrow fluid (at least 10 mL) can be collected after two attempts, you may not be able to continue (confirm with trial site)

  • For another part of the study (Study 2): If not enough fat tissue (at least 40 mL) can be collected after two attempts, you may not be able to continue (confirm with trial site)


Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Sowmya Viswanathan, PhD, University Health Network, Toronto

Phone: 416-634-7240

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
1 January 2025
Est. completion
1 June 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Pain Level Changes. Differences in response rates between groups (treatments vs placebos) at 6-months (end of study) compared to baseline. Response is based on an improvement of 2 units or more in the Numeric Pain Rating Scale (NPRS).

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov